MIM
IMVT icon

MetLife Investment Management’s Immunovant IMVT Stock Holding History

MetLife Investment Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.91M Buy
49,677
+5,216
+12% +$159K 0.01% 1179
2026
Q1 		$1.1M Buy
44,461
+5,425
+14% +$140K 0.01% 1347
2025
Q4 		$992K Sell
39,036
-1,864
-5% -$41.6K ﹤0.01% 1433
2025
Q3 		$659K Hold
40,900
– – ﹤0.01% 1679
2025
Q2 		$654K Buy
40,900
+5,805
+17% +$87.8K ﹤0.01% 1553
2025
Q1 		$600K Sell
35,095
-553
-2% -$11.6K ﹤0.01% 1632
2024
Q4 		$883K Buy
35,648
+2,040
+6% +$57.9K ﹤0.01% 1481
2024
Q3 		$958K Hold
33,608
– – 0.01% 1414
2024
Q2 		$887K Buy
33,608
+5,131
+18% +$146K 0.01% 1411
2024
Q1 		$920K Hold
28,477
– – 0.01% 1343
2023
Q4 		$1.2M Hold
28,477
– – 0.01% 1205
2023
Q3 		$1.09M Hold
28,477
– – 0.01% 1182
2023
Q2 		$540K Buy
28,477
+6,087
+27% +$114K ﹤0.01% 1648
2023
Q1 		$347K Buy
22,390
+743
+3% +$12.9K ﹤0.01% 1869
2022
Q4 		$384K Hold
21,647
– – ﹤0.01% 1814
2022
Q3 		$121K Buy
+21,647
New +$106K ﹤0.01% 2583
2022
Q2 		– Sell
-25,184
Closed -$139K – 2883
2022
Q1 		$139K Buy
25,184
+20,377
+424% +$127K ﹤0.01% 2546
2021
Q4 		$41K Sell
4,807
-10,202
-68% -$84.2K ﹤0.01% 2470
2021
Q3 		$130K Buy
15,009
+10,800
+257% +$97.4K ﹤0.01% 2322
2021
Q2 		$44.5K Sell
4,209
-10,798
-72% -$151K ﹤0.01% 2425
2021
Q1 		$241K Hold
15,007
– – ﹤0.01% 1955
2020
Q4 		$693K Hold
15,007
– – 0.01% 1310
2020
Q3 		$528K Buy
15,007
+5,560
+59% +$167K 0.01% 1340
2020
Q2 		$230K Buy
+9,447
New +$202K ﹤0.01% 1821

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MetLife Investment Management's IMVT Position: Q2 2026 in Review

MetLife Investment Management increased its Immunovant (IMVT) stake by 12% in Q2 2026, buying an estimated $159K and bringing the position to 49,677 shares worth $1.91M. The position accounts for 0.01% of the portfolio, ranked #1179.

MetLife Investment Management first reported a position in IMVT in Q2 2020 and has held it in 24 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • MetLife Investment Management held 49,677 shares of Immunovant worth $1.91M as of Q2 2026.
  • MetLife Investment Management bought 5,216 Immunovant shares in Q2 2026, an estimated $159K.
  • Immunovant made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1179 holding.
  • MetLife Investment Management first reported a position in Immunovant in Q2 2020 and has held it in 24 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.